Trials / Completed
CompletedNCT04338659
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
A Phase 1a Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Advanced Malignant Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.
Detailed description
A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection | IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection |
Timeline
- Start date
- 2021-01-14
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2020-04-08
- Last updated
- 2023-10-10
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04338659. Inclusion in this directory is not an endorsement.